ETON Eton Pharmaceuticals, Inc.

NASDAQ
$57.68

Eton Pharmaceuticals, Inc. (ETON) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is $0.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.0% since its last earnings release on August 13, 2026.

Eton Pharmaceuticals Beat Consensus Estimates, Raises Guidance
Thursday, August 13, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs $0.34
Rev est $42.21M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $59.83

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®, and has six additional products that have been submitted to the FDA.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.